Martínez-Aguirre Christopher, Carmona-Cruz Francia, Velasco Ana Luisa, Velasco Francisco, Aguado-Carrillo Gustavo, Cuéllar-Herrera Manola, Rocha Luisa
Department of Pharmacobiology, Center for Research and Advanced Studies, Mexico City, Mexico.
Epilepsy Clinic, Hospital General de México Dr. Eduardo Liceaga, Mexico City, Mexico.
Front Behav Neurosci. 2020 Dec 15;14:611278. doi: 10.3389/fnbeh.2020.611278. eCollection 2020.
Experimental evidence indicates that cannabidiol (CBD) induces anxiolytic and antiepileptic effects through the activation of 5-HT receptors. These receptors are coupled to G proteins and induce inhibitory effects. At present, the interaction of CBD with 5-HT receptors in the human brain is unknown. The aim of this study focused on evaluating the interaction between CBD and 5-HT receptors in cell membranes obtained from the hippocampus and temporal neocortex of autopsies and patients with drug-resistant mesial temporal lobe epilepsy (DR-MTLE). Cell membranes were isolated from the hippocampus and temporal neocortex of a group of patients with DR-MTLE who were submitted to epilepsy surgery ( = 11) and from a group of autopsies ( = 11). The [H]-8-OH-DPAT binding assay was used to determine the pharmacological interaction of CBD with 5-HT receptors. The [S]-GTPγS assay was used to investigate the CBD-induced activation of G proteins through its action on 5-HT receptors.The CBD affinity (p ) for 5-HT receptors was similar for autopsies and patients with DR-MTLE (hippocampus: 4.29 and 4.47, respectively; temporal neocortex: 4.67 and 4.74, respectively). Concerning the [S]-GTPγS assay, no statistically significant changes were observed for both hippocampal and neocortical tissue ( > 0.05) at low CBD concentrations (1 pM to 10 μM). In contrast, at high concentrations (100 μM), CBD reduced the constitutive activity of G proteins of autopsies and DR-MTLE patients (hippocampus: 39.2% and 39.6%, respectively; temporal neocortex: 35.2% and 24.4%, respectively). These changes were partially reversed in the presence of WAY-100635, an antagonist of 5-HT receptors, in the autopsy group (hippocampus, 59.8%, < 0.0001; temporal neocortex, 71.5%, < 0.0001) and the group of patients with DR-MTLE (hippocampus, 53.7%, < 0.0001; temporal neocortex, 68.5%, < 0.001). Our results show that CBD interacts with human 5-HT receptors of the hippocampus and temporal neocortex. At low concentrations, the effect of CBD upon G protein activation is limited. However, at high concentrations, CBD acts as an inverse agonist of 5-HT receptors. This effect could modify neuronal excitation and epileptic seizures in patients with DR-MTLE.
实验证据表明,大麻二酚(CBD)通过激活5-羟色胺(5-HT)受体产生抗焦虑和抗癫痫作用。这些受体与G蛋白偶联并产生抑制作用。目前,CBD与人脑5-HT受体之间的相互作用尚不清楚。本研究旨在评估CBD与尸检以及耐药性内侧颞叶癫痫(DR-MTLE)患者海马体和颞叶新皮质细胞膜中5-HT受体之间的相互作用。细胞膜取自一组接受癫痫手术的DR-MTLE患者(n = 11)的海马体和颞叶新皮质以及一组尸检样本(n = 11)。采用[H]-8-OH-DPAT结合试验来确定CBD与5-HT受体的药理相互作用。采用[S]-GTPγS试验来研究CBD通过作用于5-HT受体诱导G蛋白激活的情况。尸检样本和DR-MTLE患者的CBD对5-HT受体的亲和力(p)相似(海马体:分别为4.29和4.47;颞叶新皮质:分别为4.67和4.74)。关于[S]-GTPγS试验,在低CBD浓度(1 pM至10 μM)下,海马体和新皮质组织均未观察到统计学上的显著变化(P>0.05)。相反,在高浓度(100 μM)下,CBD降低了尸检样本和DR-MTLE患者G蛋白的组成性活性(海马体:分别为39.2%和39.6%;颞叶新皮质:分别为35.2%和24.4%)。在尸检组(海马体,59.8%,P<0.0001;颞叶新皮质,71.5%,P<0.0001)和DR-MTLE患者组(海马体,53.7%,P<0.0001;颞叶新皮质,68.5%,P<0.001)中,5-HT受体拮抗剂WAY-100635的存在部分逆转了这些变化。我们的结果表明,CBD与海马体和颞叶新皮质的人类5-HT受体相互作用。在低浓度下,CBD对G蛋白激活的作用有限。然而,在高浓度下,CBD作为5-HT受体的反向激动剂发挥作用。这种作用可能会改变DR-MTLE患者的神经元兴奋性和癫痫发作。